LCD L39919: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — Palmetto GBA
Policy LCD-L39919 · Hematology
New LCD may affect billing for specific myeloproliferative tests.
Code intelligence
C92.2 reimbursement alerts
Policy changes, MAC LCD updates, and CMS guidance matched to code C92.2.
Normal code riskView ICD-10 detail
Signal breakdown
2 shown · 2 total in platform
Risk: Normal
0
Critical
0%
0
High
0%
2
Routine
100%
0
Low
0%
New this month
—
alerts added in last 30 days
Effective soon
—
no upcoming deadlines
Routine
Proposed LCD DL39923: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — Noridian
Policy LCD-DL39923 · Hematology
New LCD may affect reimbursement for myeloproliferative tests.
Audit documentation
Building an audit file that includes C92.2?
The Tripwire Audit Pack exports 12 months of Hematology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
Get the Hematology audit pack — $349One-time purchase · not a subscription